Information Provided By: 
Fly News Breaks for November 25, 2019
CI
Nov 25, 2019 | 07:50 EDT
Cowen analyst Charles Rhyee said he continues to be a buyer of Cigna shares following meetings with management. He said its strong free cash flow provides optionality for capital deployment, he thinks share repurchases is more likely than M&A or a dividend increase, and its combination with Express Scripts is already producing growth in terms of new innovations and client wins. Ryhee reiterated his Outperform rating and $240 price target on Cigna shares.
News For CI From the Last 2 Days
